About Teneurin-3
Teneurin-3 (TENM3) is a protein
from Homo sapiens identified by UniProt accession
Q9P273, 2699 residues long.
MolForge cross-references it against 0 known binders and
81 disease associations.
Target properties
| Protein name | Teneurin-3 |
|---|
| UniProt accession | Q9P273 |
|---|
| Gene | TENM3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 2699 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (81)
Diseases linked to this target (Open Targets).
- microphthalmia, isolated, with coloboma · score 0.74
- neuroticism measurement · score 0.49
- hypertension · score 0.36
- neurotic disorder · score 0.33
- PHF-tau measurement · score 0.31
- smoking behavior · score 0.31
- plasma renin activity measurement · score 0.30
- schizophrenia · score 0.29
- Abnormality of refraction · score 0.26
- protein measurement · score 0.26
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9P273-F1 | alphafold | PREDICTED | 77.37 | — |
Amino-acid sequence (2699 residues)
MDVKERRPYC SLTKSRREKE RRYTNSSADN EECRVPTQKS YSSSETLKAF DHDSSRLLYG NRVKDLVHRE ADEFTRQGQN FTLRQLGVCE PATRRGLAFC AEMGLPHRGY SISAGSDADT ENEAVMSPEH AMRLWGRGVK SGRSSCLSSR SNSALTLTDT EHENKSDSEN EQPASNQGQS TLQPLPPSHK QHSAQHHPSI TSLNRNSLTN RRNQSPAPPA ALPAELQTTP ESVQLQDSWV LGSNVPLESR HFLFKTGTGT TPLFSTATPG YTMASGSVYS PPTRPLPRNT LSRSAFKFKK SSKYCSWKCT ALCAVGVSVL LAILLSYFIA MHLFGLNWQL QQTENDTFEN GKVNSDTMPT NTVSLPSGDN GKLGGFTQEN NTIDSGELDI GRRAIQEIPP GIFWRSQLFI DQPQFLKFNI SLQKDALIGV YGRKGLPPSH TQYDFVELLD GSRLIAREQR SLLETERAGR QARSVSLHEA GFIQYLDSGI WHLAFYNDGK NAEQVSFNTI VIESVVECPR NCHGNGECVS GTCHCFPGFL GPDCSRAACP VLCSGNGQYS KGRCLCFSGW KGTECDVPTT QCIDPQCGGR GICIMGSCAC NSGYKGESCE EADCIDPGCS NHGVCIHGEC HCSPGWGGSN CEILKTMCPD QCSGHGTYLQ ESGSCTCDPN WTGPDCSNEI CSVDCGSHGV CMGGTCRCEE GWTGPACNQR ACHPRCAEHG TCKDGKCECS QGWNGEHCTI EGCPGLCNSN GRCTLDQNGW HCVCQPGWRG AGCDVAMETL CTDSKDNEGD GLIDCMDPDC CLQSSCQNQP YCRGLPDPQD IISQSLQSPS QQAAKSFYDR ISFLIGSDST HVIPGESPFN KSLASVIRGQ VLTADGTPLI GVNVSFFHYP EYGYTITRQD GMFDLVANGG ASLTLVFERS PFLTQYHTVW IPWNVFYVMD TLVMKKEEND IPSCDLSGFV RPNPIIVSSP LSTFFRSSPE DSPIIPETQV LHEETTIPGT DLKLSYLSSR AAGYKSVLKI TMTQSIIPFN LMKVHLMVAV VGRLFQKWFP ASPNLAYTFI WDKTDAYNQK VYGLSEAVVS VGYEYESCLD LTLWEKRTAI LQGYELDASN MGGWTLDKHH VLDVQNGILY KGNGENQFIS QQPPVVSSIM GNGRRRSISC PSCNGQADGN KLLAPVALAC GIDGSLYVGD FNYVRRIFPS GNVTSVLELS SNPAHRYYLA TDPVTGDLYV SDTNTRRIYR PKSLTGAKDL TKNAEVVAGT GEQCLPFDEA RCGDGGKAVE ATLMSPKGMA VDKNGLIYFV DGTMIRKVDQ NGIISTLLGS NDLTSARPLT CDTSMHISQV RLEWPTDLAI NPMDNSIYVL DNNVVLQITE NRQVRIAAGR PMHCQVPGVE YPVGKHAVQT TLESATAIAV SYSGVLYITE TDEKKINRIR QVTTDGEISL VAGIPSECDC KNDANCDCYQ SGDGYAKDAK LSAPSSLAAS PDGTLYIADL GNIRIRAVSK NKPLLNSMNF YEVASPTDQE LYIFDINGTH QYTVSLVTGD YLYNFSYSND NDITAVTDSN GNTLRIRRDP NRMPVRVVSP DNQVIWLTIG TNGCLKSMTA QGLELVLFTY HGNSGLLATK SDETGWTTFF DYDSEGRLTN VTFPTGVVTN LHGDMDKAIT VDIESSSREE DVSITSNLSS IDSFYTMVQD QLRNSYQIGY DGSLRIIYAS GLDSHYQTEP HVLAGTANPT VAKRNMTLPG ENGQNLVEWR FRKEQAQGKV NVFGRKLRVN GRNLLSVDFD RTTKTEKIYD DHRKFLLRIA YDTSGHPTLW LPSSKLMAVN VTYSSTGQIA SIQRGTTSEK VDYDGQGRIV SRVFADGKTW SYTYLEKSMV LLLHSQRQYI FEYDMWDRLS AITMPSVARH TMQTIRSIGY YRNIYNPPES NASIITDYNE EGLLLQTAFL GTSRRVLFKY RRQTRLSEIL YDSTRVSFTY DETAGVLKTV NLQSDGFICT IRYRQIGPLI DRQIFRFSED GMVNARFDYS YDNSFRVTSM QGVINETPLP IDLYQFDDIS GKVEQFGKFG VIYYDINQII STAVMTYTKH FDAHGRIKEI QYEIFRSLMY WITIQYDNMG RVTKREIKIG PFANTTKYAY EYDVDGQLQT VYLNEKIMWR YNYDLNGNLH LLNPSNSARL TPLRYDLRDR ITRLGDVQYR LDEDGFLRQR GTEIFEYSSK GLLTRVYSKG SGWTVIYRYD GLGRRVSSKT SLGQHLQFFY ADLTYPTRIT HVYNHSSSEI TSLYYDLQGH LFAMEISSGD EFYIASDNTG TPLAVFSSNG LMLKQIQYTA YGEIYFDSNI DFQLVIGFHG GLYDPLTKLI HFGERDYDIL AGRWTTPDIE IWKRIGKDPA PFNLYMFRNN NPASKIHDVK DYITDVNSWL VTFGFHLHNA IPGFPVPKFD LTEPSYELVK SQQWDDIPPI FGVQQQVARQ AKAFLSLGKM AEVQVSRRRA GGAQSWLWFA TVKSLIGKGV MLAVSQGRVQ TNVLNIANED CIKVAAVLNN AFYLENLHFT IEGKDTHYFI KTTTPESDLG TLRLTSGRKA LENGINVTVS QSTTVVNGRT RRFADVEMQF GALALHVRYG MTLDEEKARI LEQARQRALA RAWAREQQRV RDGEEGARLW TEGEKRQLLS AGKVQGYDGY YVLSVEQYPE LADSANNIQF LRQSEIGRR
Explore Teneurin-3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets